Tardive Dyskinesia

Here are highlights from the third day of this year’s APA Annual Meeting.

New research on tardive dyskinesia has also been featured at the 2024 APA Annual Meeting.

This 2024 APA Annual Meeting poster estimated the prevalence of tardive dyskinesia in antipsychotic users in the US, and found rates ranging from 94.1-127.4 per 1000 antipsychotic users.

Deutetrabenazine extended-release tablets are now available.

A new, easy-to-use scale might be able to help clinicians determine the impact of tardive dyskinesia on patient functioning.

How do race, age, and gender correlate with the risk of tardive dyskinesia?

In this custom video series, experts share overall impressions of a female patient with bipolar 1 disorder who develops new onset movements suggesting tardive dyskinesia and the rationale for intervening with VMAT2 therapy.

In this custom video series, Leslie L. Citrome, MD, MPH, and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, review the case of a male patient with schizophrenia who develops symptoms of tardive dyskinesia and comments on the appropriateness for intervening with VMAT2 inhibitor therapy.

What do we know about TD? What is on the horizon? Take the quiz to learn more.

How could drugs that block post-synaptic dopamine 2 receptors increase the risk for tardive dyskinesia over time?

Major risk factors for onset of tardive dyskinesia are considered.

What major challenges do patients with tardive dyskinesia face in their daily lives? Take the quiz and learn more.

The first study to gather unsolicited patient responses via social media finds 3 negative themes.

Learn about the results of the recent study on deutetrabenazine and the ways it is helping patients with tardive dyskinesia.

There are a few things that we all agree on, as reflected in a recent consensus statement.